Meta-analysis: Cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis

European Journal of Gastroenterology and Hepatology

Volumn 23, Issue 10, 2011, Pages 876-880

  Wang, Xin ^a   Tian, Hui Jin ^b   Yang, Hu Ke ^a   Wanyan, Pingping ^a   Peng, Ye Ji ^a  

^a LANZHOU UNIVERSITY   (China)

^b North West Normal University   (China)

Author keywords

cyclooxygenase 2 inhibitors; gastrointestinal symptoms; nonselective nonsteroidal anti inflammatory drugs; upper gastrointestinal

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; LANSOPRAZOLE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ADJUVANT THERAPY; ARTICLE; BRAIN HEMORRHAGE; BRONCHOPNEUMONIA; CARDIOVASCULAR DISEASE; COLON CANCER; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; GASTROINTESTINAL SYMPTOM; HEART ARREST; HUMAN; LUNG CANCER; LUNG EMBOLISM; META ANALYSIS; OSTEOARTHRITIS; PERITONITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; RISK FACTOR; SMALL INTESTINE PERFORATION; SYSTEMATIC REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2 INHIBITORS; DRUG THERAPY, COMBINATION; GASTROINTESTINAL DISEASES; HUMANS; OSTEOARTHRITIS; PROTON PUMP INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 80052674722     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328349de81     Document Type: Article

References (35)

1. Elders MJ. The increasing impact of arthritis on public health. J Rheumatol Suppl 2000; 60:6-8.
2. Andrianakos AA, Kontelis LK, Karamitsos DG, Aslanidis SI, Georgountzos AI, Kaziolas GO, et al. Prevalence of symptomatic knee, hand, and hip osteoarthritis in Greece. The ESORDIG study 2006; 33:2507-2513.
3. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008; 58:26-35.
4. Grotle M, Hagen KB, Natvig B, Dahl FA, Kvien TK. Prevalence and burden of osteoarthritis: results from a population survey in Norway. J Rheumatol 2008; 35:677-684. (Pubitemid 351500066)
5. Symmons D, Turner G, Webb R, Asten P, Barrett E, Lunt M, et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology (Oxford) 2002; 41:793-800. (Pubitemid 34822963)
6. Sale JE, Gignac M, Hawker G. The relationship between disease symptoms, life events, coping and treatment, and depression among older adults with osteoarthritis. J Rheumatol 2008; 35:335-342. (Pubitemid 351281157)
7. Salaffi F, Carotti M, Stancati A, Grassi W. Health-related quality of life in older adults with symptomatic hip and knee osteoarthritis: a comparison with matched healthy controls. Aging Clin Exp Res 2005; 17:255-263. (Pubitemid 46190142)
8. Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther KP, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005; 64:669-681. (Pubitemid 40559291)
9. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000; 43:1905-1915.
10. Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62:1145-1155. (Pubitemid 37500619)
11. Chan TY, Critchley JA, Lau JT, Sung JJ, Chung SS, Anderson DC. The relationship between upper gastrointestinal hemorrhage and drug use: a case control study. Int J Clin Pharmacol Ther 1996; 34:304-308. (Pubitemid 26235418)
12. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520-1528.
13. Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004; 364:665-674. (Pubitemid 39140622)
14. Laine L. Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs-nice or necessary? Rev Gastroenterol Disord 2004; 4:S33-S41.
15. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006; 296:1633-1644. (Pubitemid 44511610)
16. Singh G, Fort JG, Goldstein JL, Levy RA, Hanrahan PS, Bello AE, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med 2006; 119:255-266. (Pubitemid 43255067)
17. Hasselgren G, Keelan M, Kirdeikis P, Lee J, Röhss K, Sinclair P, et al. Optimization of acid suppression for patients with peptic ulcer bleeding: an intragastric pH-metry study with omeprazole. Eur J Gastroenterol Hepatol 1998; 10:601-606. (Pubitemid 28330609)
18. Scheiman JM, Yeomans ND, Talley NJ, Vakil N, Chan FK, Tulassay Z, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 2006; 101:701-710.
19. Leontiadis GI, Sreedharan A, Dorward S, Barton P, Delaney B, Howden CW, et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess 2007; 11:1-164.
20. Laine L, Margolis J, Brown K. Use of GI protective agents and COX-2 selective inhibitors in 14394 624 U.S. patients taking NSAIDs. Gastroenterology 2004; 126:A36-A37.
21. Schnitzer TJ. Update on guidelines for the treatment of chronic musculoskeletal pain. Clin Rheumatol 2006; 25:S22-S29. (Pubitemid 43933679)
22. Chan FK, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010; 376:173-179.
23. Chan FK, Hung LC, Suen BY, Wong VW, Hui AJ, Wu JC, et al. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology 2004; 127:1038-1043. (Pubitemid 39345872)
24. Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002; 347:2104-2110. (Pubitemid 36015122)
25. Chan FK, Leung WK, Suen BY, Lee K, Lee YT, Wu JC, et al. A double-blinded randomized comparison of celecoxib verusus omeprazole and diclofenac for secondary prevention of ulcer bleeding in chronic NSAID users. Gastroenterology 2001; 120:A143.
26. Goldstein JL, Cryer B, Amer F, Hunt B. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial. Clin Gastroenterol Hepatol 2007; 5:1167-1174. (Pubitemid 47488966)
27. Lai KC, Chu KM, Hui WM, Wong BC, Hu WH, Wong WM, et al. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med 2005; 118:1271-1278. (Pubitemid 41566529)
28. Higgins JPT, Green S. eds. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.0.2 (updated September 2008). The Cochrane Collaboration 2008. Available at: http://www.cochrane-handbook.org.
29. Laine L, White WB, Rostom A, Hochberg M. COX-2 selective inhibitors in the treatment of osteoarthritis. Semin Arthritis Rheum 2008; 38:165-187.
30. Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999; 354:2106-2111. (Pubitemid 30008893)
31. Garner SE, Fidan D, Frankish RR, Judd M, Shea B, Towheed T, et al. Celecoxib for rheumatoid arthritis. Cochrane Database Syst Rev 2002;CD003831. doi:10.1002/14651858.
32. Vonkeman HE, van de Laar MA. Nonsteroidal anti-inflammatory drugs: adverse effects and their prevention. Semin Arthritis Rheum 2010; 39:294-312.
33. Schlansky B, Hwang JH. Prevention of nonsteroidal anti-inflammatory drug-induced gastropathy. J Gastroenterol 2009; 44:44-52.
34. Vane JR, Bakhle1 YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998; 38:97-120. (Pubitemid 28231490)
35. Chen YF, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2008; 12:1-278.